Lynparza Shortage: What Providers and Prescribers Need to Know in 2026

For providers prescribing Lynparza (olaparib), the good news is that supply is not the problem—Lynparza is not on the FDA Drug Shortages database as of 2026, and AstraZeneca has maintained consistent manufacturing output. The practical challenge, however, lies in the layers of administrative and financial barriers that stand between your prescription and your patient actually taking the medication.

This guide covers the current landscape for Lynparza prescribers in 2026: what to anticipate, how to streamline access, and how to advocate for your patients when barriers arise.

Current Availability Status

Lynparza 100 mg and 150 mg film-coated tablets are commercially available in the United States through specialty pharmacy channels. There are no current FDA-tracked supply disruptions. AstraZeneca distributes Lynparza through a specialty pharmacy network via its Access 360 hub, which coordinates dispensing from specialty pharmacies including CVS Specialty, Walgreens Specialty, Accredo, and hospital-affiliated outpatient pharmacies.

The Real Access Barriers: What Providers Need to Know

1. Prior Authorization: The Primary Access Bottleneck

Prior authorization is required by the vast majority of commercial payers and Medicare Part D plans covering Lynparza. PA criteria typically require:

Confirmed cancer diagnosis matching an FDA-approved Lynparza indication

Documented BRCA1/2 or HRR gene mutation from an FDA-approved companion diagnostic

Evidence of appropriate prior chemotherapy and treatment response (for maintenance indications)

ECOG performance status documentation in some plans

If your practice does not have robust PA support staff, enrolling patients in AstraZeneca's Access 360 program (1-844-275-2360) delegates much of this work to dedicated case managers. Access 360 has visibility into individual payer requirements and can often expedite the process.

2. Companion Diagnostic Timing: Plan Ahead

Every FDA-approved indication for Lynparza requires patient selection based on a companion diagnostic. Germline testing (for BRCA1/2) and somatic/tumor testing (for HRR genes) can take 1–4 weeks depending on the laboratory. For patients who will be transitioning to Lynparza maintenance therapy after platinum-based chemotherapy:

Order genetic testing early—ideally during chemotherapy, not after it's completed

Ensure results are documented in the medical record in a format that meets payer PA requirements

Confirm the testing laboratory is using an FDA-approved companion diagnostic platform

3. Specialty Pharmacy Navigation

Lynparza cannot be dispensed through standard retail pharmacies. Prescriptions must be routed to a specialty pharmacy. If your practice has a preferred specialty pharmacy partner, route prescriptions there directly. If not, Access 360 can coordinate specialty pharmacy dispensing based on the patient's insurance network and geography.

For patients who cannot easily access a local specialty pharmacy—particularly those in rural or underserved areas—mail-order specialty pharmacy options are available and may also provide cost advantages for patients with certain insurance plans.

4. Financial Barriers: A Critical Issue for Oncology Patients

At a retail price of approximately $17,000–$20,000/month, cost is a significant barrier for uninsured, underinsured, and even some commercially insured patients. Key programs to know:

Lynparza Co-pay Savings Program: Eligible commercially insured patients may pay as little as $0/month, with savings of up to $26,000/year. No income requirement. Enroll via Access 360.

AZ&Me Prescription Savings: Provides Lynparza at no cost to qualifying uninsured or underinsured patients. Income-based eligibility. Enrollment every 12 months, 90-day supply delivery.

Independent foundations: Organizations like the Patient Advocate Foundation and CancerCare can provide supplemental copay and premium assistance for Medicare patients not eligible for manufacturer copay programs.

5. Managing Bridge Therapy During PA Delays

When PA approval is delayed—especially in the post-chemotherapy window when maintenance therapy should ideally begin—providers should:

Request bridge supply through Access 360 (available for eligible patients while PA is pending)

Document the clinical urgency in any PA submission or appeal

Consider requesting expedited PA review given the time-sensitive nature of post-platinum maintenance therapy

How medfinder Supports Providers

For practices that want to help patients locate specialty pharmacies carrying Lynparza in their area without the phone-call burden, medfinder for providers can do the pharmacy canvassing on behalf of your patients. This is particularly helpful in rural or underserved markets where specialty pharmacy access is less concentrated.

Key Prescribing and Monitoring Reminders

Standard dose: 300 mg (two 150 mg tablets) orally twice daily

CYP3A interactions: Strong CYP3A inhibitors (e.g., ketoconazole, ritonavir) require dose reduction to 100 mg BID. Strong inducers (e.g., rifampin, carbamazepine) should be avoided.

Hematologic monitoring: CBC at baseline and monthly. MDS/AML occurs in ~1.2% of patients; refer to hematology if prolonged cytopenias occur.

Pregnancy: Verify pregnancy status before initiation. Advise females to use contraception during treatment and for 6 months after; males for 3 months after last dose.

For a more detailed practical guide on helping your patients access Lynparza, see How to Help Your Patients Find Lynparza in Stock: A Provider's Guide.